← All reports

The European Medicines Agency defends the effectiveness of Alzheimer’s drugs despite a study questioning their benefits.

HealthcareLegal IssuesApr 22, 2026score 0.272 posts · 0 replies across 2 instances
The EU regulator is defending Alzheimer’s drugs following a study that questions their benefits. The European Medicines Agency states that the review does not provide a clear picture of the effectiveness of EU treatments for Alzheimer’s.

Claims

The European Medicines Agency defends the effectiveness of Alzheimer’s drugs despite a study questioning their benefits.
Parent: HealthcareEntity: Alzheimer’s drugsImpact: negativeDate: Apr 22, 2026Target: The effectiveness of Alzheimer’s drugs

Source posts

@[email protected]
EU regulator defends Alzheimer’s drugs after study questions benefits https://www.euractiv.com/news/eu-regulator-defends-alzheimers-drugs-after-study-questions-benefits/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv%40masto.ai
0 boosts · 0 favs · 0 replies · Apr 22, 2026
@[email protected]
EU regulator defends Alzheimer’s drugs after study questions benefits: European Medicines Agency says review doesn't paint a clear picture of EU treatments https://www.euractiv.com/news/eu-regulator-defends-alzheimers-drugs-after-study-questions-benefits/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv_economy%40eupolicy.social
0 boosts · 0 favs · 0 replies · Apr 22, 2026